PROF logo

PROFOUND MEDICAL CORP

PROFNASDAQ
Earnings Mar 3 Β· PostUS Equity
$6.40β–Ό $0.32 (βˆ’4.83%)
Market closed Β· at close
πŸ””
Track PROF
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 4.8%
7dβ–Ό 13.9%
14dβ–Ό 11.1%
30dβ–² 14.9%
ytdβ–Ό 19.0%
1yβ–² 6.7%
🏦Market Cap
$234M
Small Cap
πŸ“ˆRevenue Growth (YoY)
65.3%
High Growth
πŸ“ŠGross Margin
73.9%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
10.3x
Elevated
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$6.29 – $6.65
52-Week Range
$6.52 – $12.40
Volume (shares)
7,411
Avg Volume (shares)
β€”
Shares Outstanding
36.6M
Next Earnings
2027-03-03

Fundamentals Snapshot

Annual Revenue
$16M
Last Q Revenue
$10M
P/E Ratio
β€”
P/S Ratio
10.3x
EPS (TTM)
$-0.94
Dividend Yield
β€”
Dilution (1yr)
+19.2%
PROF logo

PROFOUND MEDICAL CORP

PROF
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$16Mβ–² +61.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
70.8%β–² +7.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$42Mβ–² +33.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$39Mβ–² +66.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
30.7Mβ–² +19.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$55Mβ–² +$5M YoY
StockOtter Β· stockotter.space

About PROFOUND MEDICAL CORP

Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.